Effect of inhibiting Pim-1 kinase in acute myeloid leukemia with FLT3 internal tandem duplication
AdvisorBaer, Maria R.
MetadataShow full item record
AbstractThe project is focused on combinatorial treatment involving downstream inhibitors of FLT3 signaling, representing a promising approach for treating AML patients with FLT3-ITD. Pim-1 kinase is upregulated downstream of FLT3-ITD pathway by a positive feedback loop. The goal of this work was to characterize Pim kinase inhibitor (PIM447, currently in clinical trials) sensitization of cells FLT3-ITD to apoptosis induction by combination of FLT3 inhibitors and chemotherapy drugs. PIM447 sensitizes FLT3-ITD cells to FLT3 inhibitors and topoisomerase-2 inhibitors. Co-treatment with the Pim kinase inhibitor AZD1208 and FLT3 inhibitor quizartinib was found to enhance apoptosis of cells FLT3-ITD post-translationally, decreasing expression of the anti-apoptotic protein Mcl-1 through increased proteasomal degradation and in association with decreased expression of deubiquitinase USP9X. PIM447 in combination with FLT3 inhibitors as quizartinib, sorafenib and midostaurin and topoisomerase-2 inhibitors as daunorubicin, mitoxantrone and etoposide in FLT3-ITD cells, induced a dose response dependent increasing apoptosis.
DescriptionUniversity of Maryland, Baltimore. Medical and Research Technology. M.S. 2016
KeywordDrug Therapy, Combination
Leukemia, Myeloid, Acute--drug therapy
Proto-Oncogene Proteins c-pim-1--antagonists & inhibitors